Figure 1
Correlation of BRAF, NRAS, c-KIT mutation and clinico-pathological features of melanoma, all patients (N = 230)
| BRAF | NRAS | c-KIT | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| mutation | wild type | P | mutation | wild type | P | mutation | wild type | P | ||
| 129 (56.1%) | 101 (43.9%) | 31 (15.1%) | 174 (84.9%) | 3 (1.5%) | 202 (98.5%) | |||||
| Age (years; mean) | 52.3 | 59.3 | < 0.05 | 61.4 | 54.7 | < 0.05 | 63.4 | 54.9 | N.A. | |
| Gender | male | 82 (63.6%) | 59 (58.4%) | 0.43 | 19 (61.3%) | 113 (64.9%) | 0.62 | 2 (66.7%) | 130 (64.4%) | N.A. |
| female | 47 (36.4%) | 42 (41.6%) | 12 (38.7%) | 61 (35.1%) | 1 (33.3%) | 72 (35.6%) | ||||
| Histological subtypes due to low number of specified groups results should be interpreted carefully | ||||||||||
| SSM | 40 (31.0%) | 21 (20.8%) | < 0.05 due to low number of specified groups results should be interpreted carefully | 6 (19.3%) | 46 (26.4%) | 0.59 due to low number of specified groups results should be interpreted carefully | 0 (0.0%) | 52 (25.7%) | N.A. | |
| NM | 22 (17.1%) | 23 (22.8%) | 10 (32.3%) | 33 (19.0%) | 2 (66.7%) | 41 (20.3%) | ||||
| ALM | 0 (0.0%) | 1 (1.0%) | 0 (0.0%) | 1 (0.6%) | 0 (0.0%) | 1 (0.5%) | ||||
| LMM | 1 (0.8%) | 3 (3.0%) | 0 (0.0%) | 3 (1.7%) | 0 (0.0%) | 3 (1.5%) | ||||
| other | 3 (2.3%) | 11 (10.9%) | 2 (6.5%) | 9 (5.1%) | 1 (33.3%) | 10 (5.0%) | ||||
| NOS | 63 (48.8%) | 42 (41.5%) | 13 (41.9%) | 82 (47.2%) | 0 (0.0%) | 95 (47.0%) | ||||
| Site of primary | ||||||||||
| head and neck | 12 (9.3%) | 12 (11.9%) | 0.46 | 1 (3.2%) | 21 (12.1%) | 0.56 | 0 (0.0%) | 22 (10.9%) | N.A. | |
| trunk | 63 (48.8%) | 28 (27.8%) | 10 (32.2%) | 70 (40.2%) | 1 (33.3%) | 79 (39.1%) | ||||
| extremities | 25 (19.4%) | 27 (26.7%) | 12 (38.8%) | 33 (19.0%) | 1 (33.3%) | 44 (21.7%) | ||||
| unknown | 27 (20.9%) | 18 (17.8%) | 8 (25.8%) | 35 (20.1%) | 0 (0.0%) | 43 (21.3%) | ||||
| mucosal | 0 (0.0%) | 7 (6.9%) | 0 (0.0%) | 7 (4.0%) | 1 (33.3%) | 6 (3.0%) | ||||
| uveal | 2 (1.6%) | 9 (8.9%) | 0 (0.0%) | 8 (4.6%) | 0 (0.0%) | 8 (4.0%) | ||||
| Initially metastatic disease | ||||||||||
| Yes | 36 (27.9%) | 25 (24.8%) | 0.59 | 10 (32.2%) | 47 (27.0%) | 0.73 | 1 (33.3%) | 56 (27.7%) | N.A. | |
| No | 93 (72.1%) | 76 (75.2%) | 21 (67.8%) | 127 (73.0%) | 2 (66.7%) | 146 (72.3%) | ||||
Patient demographic and clinical characteristics of primary melanoma
| Number of patient (N = 230) | % of all patient | |
|---|---|---|
| Gender | ||
| male | 141 | 61.3 |
| female | 89 | 38.7 |
| Age at the time of diagnosis (years) | ||
| < 50 | 78 | 33.9 |
| 50 – 59 | 58 | 25.2 |
| 60 – 69 | 55 | 23.9 |
| > 69 | 39 | 17.0 |
| Location of primary tumour | ||
| cutaneous | ||
| trunk | 91 | 39.6 |
| extremities | 52 | 22.6 |
| head and neck | 24 | 10.4 |
| uveal | 11 | 4.8 |
| mucusal | 7 | 3.0 |
| occult | 45 | 19.6 |
| Tumour stages at diagnosis | ||
| in situ | 1 | 0.4 |
| localised | 67 | 29.1 |
| regional | 116 | 50.5 |
| distant | 46 | 20.0 |
Histopathological characteristic of cutaneous melanoma (N = 167)
| Number of patient (N = 167) | % of all patient | Mean | Range | |
|---|---|---|---|---|
| Melanoma subtype | ||||
| SSM | 61 | 36.6 | ||
| NM | 45 | 26.9 | ||
| ALM | 1 | 0.6 | ||
| LMM | 4 | 2.4 | ||
| NOS | 54 | 32.3 | ||
| Other | 2 | 1.2 | ||
| Clark | 3.8 | (2.0–5.0) | ||
| Breslow | 4.8 | (0.2–48.0) | ||
| Mitotic index | 8.4 | (0.0–60.0) | ||
| Ulceration | 81 | 48.5 |
Mutation of BRAF, NRAS and c-KIT
| Number of wild type (%) | Number of mutation (%) | Type | |
|---|---|---|---|
| BRAF (N = 230) | 101 (43.9%) | 129 (56.1%) | |
| 114 (49.6%) | V600E: Val600Glu (c.1799T>A) | ||
| 15 (6.5%) | V600K: Val600Lys (c.1798_1799GT>AA) | ||
| NRAS in 25 cases NRAS and c-KIT analysis was not completed due to inadequact tissue samples | 174 (84.9%) | 31 (15.1%) | |
| 10 (4.9%) | c.181C>A p.(Gln61Lys) | ||
| 14 (6.7%) | c.182A>G p.(Gln61Arg) | ||
| 2 (1.0%) | c.182A>T p.(Gln61Leu) | ||
| 1 (0.5%) | c.34G>T p.(Gly12Cys) | ||
| 3 (1.5%) | c.37G>C p.(Gly13Arg) | ||
| 1 (0.5%) | c.183A>C p.(Gln61His) | ||
| c-KIT in 25 cases NRAS and c-KIT analysis was not completed due to inadequact tissue samples | 202 (98.5%) | 3 (1.5%) | |
| 2 (1.0%) | c.1676T>C p.(Val559Ala) | ||
| 1 (0.5%) | c.1727T>C p.(Leu576Pro) |